Zelira Therapeutics Limited (ASX:ZLD)
Australia · Delayed Price · Currency is AUD 0.5000
0.00 (0.00%)
Feb 27, 2026, 3:55 PM AEST
Zelira Therapeutics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 0.01 | 0.59 | 0.15 | 2.75 | 4.97 |
Cash & Short-Term Investments | 0.01 | 0.59 | 0.15 | 2.75 | 4.97 |
Cash Growth | -99.03% | 300.91% | -94.68% | -44.75% | 192.93% |
Accounts Receivable | 0 | 0.01 | -0.01 | 0.1 | 0.04 |
Other Receivables | 0.03 | 2.3 | 0.01 | 0.16 | 0.02 |
Receivables | 0.03 | 2.31 | -0 | 0.26 | 0.06 |
Inventory | 0.48 | 1.25 | 1.53 | 1.96 | 0.87 |
Prepaid Expenses | 0.1 | 0.11 | 0.1 | 0.12 | 0.19 |
Total Current Assets | 0.61 | 4.26 | 1.77 | 5.08 | 6.09 |
Property, Plant & Equipment | 0.12 | 0.23 | 0.52 | 0.85 | 1.24 |
Long-Term Investments | - | - | - | - | 0.07 |
Goodwill | - | - | 30.75 | 30.75 | - |
Other Intangible Assets | 0.52 | 0.65 | 0.81 | 0.97 | 31.87 |
Other Long-Term Assets | 0.04 | 0.04 | 0.04 | 0.06 | 0.1 |
Total Assets | 1.3 | 5.18 | 33.89 | 37.7 | 39.37 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 3.45 | 3.41 | 1.74 | 1.51 | 0.98 |
Short-Term Debt | 1.99 | 3.54 | - | - | - |
Current Portion of Leases | 0.15 | 0.15 | 0.14 | 0.12 | 0.09 |
Total Current Liabilities | 5.59 | 7.09 | 1.88 | 1.63 | 1.08 |
Long-Term Debt | - | 2.11 | - | - | - |
Long-Term Leases | - | 0.15 | 0.3 | 0.38 | 0.46 |
Total Liabilities | 5.59 | 9.36 | 2.18 | 2.01 | 1.54 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 45.52 | 45.52 | 45.52 | 43.75 | 36.65 |
Retained Earnings | -84.96 | -81.34 | -44.77 | -39.19 | -27.25 |
Comprehensive Income & Other | 34.98 | 31.31 | 31.05 | 30.65 | 28.43 |
Total Common Equity | -4.46 | -4.51 | 31.8 | 35.2 | 37.83 |
Minority Interest | 0.17 | 0.34 | -0.09 | 0.49 | - |
Shareholders' Equity | -4.29 | -4.17 | 31.71 | 35.69 | 37.83 |
Total Liabilities & Equity | 1.3 | 5.18 | 33.89 | 37.7 | 39.37 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Total Debt | 2.14 | 5.95 | 0.44 | 0.5 | 0.55 |
Net Cash (Debt) | -2.14 | -5.36 | -0.29 | 2.25 | 4.42 |
Net Cash Growth | - | - | - | -49.20% | 315.14% |
Net Cash Per Share | -0.19 | -0.47 | -0.03 | 0.28 | 0.67 |
Filing Date Shares Outstanding | 11.9 | 11.35 | 11.35 | 9.58 | 6.8 |
Total Common Shares Outstanding | 11.9 | 11.35 | 11.35 | 9.58 | 6.8 |
Working Capital | -4.98 | -2.83 | -0.11 | 3.45 | 5.01 |
Book Value Per Share | -0.37 | -0.40 | 2.80 | 3.68 | 5.56 |
Tangible Book Value | -4.98 | -5.17 | 0.24 | 3.49 | 5.96 |
Tangible Book Value Per Share | -0.42 | -0.46 | 0.02 | 0.36 | 0.88 |